Anti-Angiogenic Therapies for Children with Cancer

Warning

This publication doesn't include Faculty of Education. It includes Faculty of Medicine. Official publication website can be found on muni.cz.
Authors

ANDRÉ N. ROSSLER J. VERSCHUUR A. ŠTĚRBA Jaroslav ROSSLER J. ŠTĚRBA Jaroslav

Year of publication 2010
Type Article in Periodical
Magazine / Source Current Cancer Drug Targets
MU Faculty or unit

Faculty of Medicine

Citation
Doi http://dx.doi.org/10.2174/156800910793357899
Field Paediatry
Keywords Children; oncology; angiogenesis; treatment; metronomic; VEGF; Tyrosine kinase inhibitors
Description Tumor angiogenesis, i.e. the development of neovascularisation in and around solid tumors, plays a key role in the local and distant growth of cancer and anti-angiogenic treatments are now established strategies to treat cancer patients. Specific inhibitors of angiogenesis such as bevacizumab or receptor tyrosine kinase inhibitors targeting VEGFR or PDGFR are now in clinical trials and are being increasingly validated for the treatment of poor prognostic cancers. Other anti-angiogenic strategies such as cilengitide or metronomic chemotherapy (low-dose anti-angiogenic chemotherapy) have been developed to treat certain types of adult cancer. In children, the clinical potential of anti-angiogenic approach is still in an early stage of investigation. This review will focus on the role of angiogenesis in pediatric solid tumors and will describe the pre-clinical and clinical experience with several anti-angiogenic compounds as a potential treatment for children with cancer.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.